Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers

被引:82
作者
Gallicano, K
Foster, B
Choudhri, S
机构
[1] Clin Invest Unit, Ottawa, ON, Canada
[2] Ottawa Hosp, Inst Res, Ottawa, ON, Canada
[3] Hlth Canada, Therapeut Prod Directorate, Ottawa, ON K1A 0L2, Canada
[4] Univ Manitoba, Dept Med, Winnipeg, MB R3T 2N2, Canada
[5] Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada
[6] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada
关键词
garlic supplements; pharmacokinetic interaction; ritonavir;
D O I
10.1046/j.1365-2125.2003.01736.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To evaluate the effect of acute dosing of garlic supplements on the single-dose pharmacokinetics of ritonavir. Methods Ten healthy volunteers (five male, five female) were equally randomized in a crossover design to receive 400 mg of a single dose of ritonavir within 10 min after eating breakfast either alone or with 10 mg of Natural Source Odourless Garlic. They received a total of eight doses of garlic extract (2 x 5 mg capsules) taken twice daily for 4 days. Ritonavir and the seventh garlic dose were administered simultaneously. Resulst Coadministration of garlic nonsignificantly decreased area under the plasma concentration-time curve (AUC(0,infinity)) by -17% (90% confidence interval (CI), -31% to 0%; range -46% to 68%) and peak plasma concentration of ritonavir by -1% (90% CI, -25% to 31%; range -51% to 136%). Conclusions Acute dosing of the garlic capsules over 4 days did not significantly alter the single-dose pharmacokinetics of ritonavir in healthy volunteers. Given the complex effects of both ritonavir and garlic on drug metabolism, the results of our study should not be extrapolated to steady-state conditions, where the possibility of an interaction still needs to be evaluated.
引用
收藏
页码:199 / 202
页数:4
相关论文
共 24 条
  • [21] A first-in-human, randomized, do.ible-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers
    Youngberg, Stephen
    Brandt, Erin
    Barve, Avantika
    Machineni, Surendra
    Jones, Christopher T.
    Dabovic, Kristina
    Jones, Catherine L.
    Colvin, Richard A.
    JOURNAL OF DRUG ASSESSMENT, 2018, 7 (01) : 66 - 74
  • [22] Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers
    Kakuda, Thomas N.
    Van De Casteele, Tom
    Petrovic, Romana
    Neujens, Mark
    Salih, Hiba
    Opsomer, Magda
    Hoetelmans, Richard M. W.
    ANTIVIRAL THERAPY, 2014, 19 (06) : 597 - 606
  • [23] Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male SubjectsPhase I Randomized, Open-Label, Two-Way Crossover Study
    V. Sekar
    E. Lefebvre
    T. De Marez
    M. De Pauw
    E. De Paepe
    T. Vangeneugden
    R. M. W. Hoetelmans
    Clinical Drug Investigation, 2008, 28 : 479 - 485
  • [24] A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers
    Zhao, Nan
    Jia, Bo
    Zhao, Hong
    Xu, Junyu
    Sheng, Xiaoyan
    Luo, Lin
    Huang, Zhangma
    Wang, Xingan
    Ren, Qingyun
    Zhang, Yingjun
    Zhao, Xia
    Cui, Yimin
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (01)